🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting in excess of 82 million instances annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval marks a significant shift in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which involves two antibiotics. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians directly involved have shared positive views. Having a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.